drugset / Trial / NCT06456424
Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection
Phase 1/2
Active not recruiting
1 enrolled
University of Calgary
Precisio Biotix Therapeutics, Inc. · collabUniversity of Toronto · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of a bacteriophage cocktail to treat and prevent the recurrence of a methicillin-susceptible Staphylococcus aureus prosthetic joint infection of the hip. The patient has exhausted all conventional therapies, both surgical and medical, at considerable detriment to his quality of life. The treatment involves a one time, intra-operative injection of bacteriophages into the joint and 14 days of intravenous phage therapy. The goal is to eliminate the infection and prevent further complications, providing a potential new treatment avenue for patients with difficult-to-treat infections.
Timeline
- Start
- 2024-11-20
- Primary completion
- 2025-11
- Completion
- 2025-11